Serum 5′-Nucleotidase as a Novel Predictor of Adverse Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease
Background: The correlation between 5′-Nucleotidase (5′-NT) and the clinical outcomes in coronary artery disease (CAD) patients following percutaneous coronary intervention (PCI) is not clear. This study aims to clarify this relationship. Methods: The PRACTICE study enrolled 15,250 patients between...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
IMR Press
2024-01-01
|
Series: | Reviews in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.imrpress.com/journal/RCM/25/1/10.31083/j.rcm2501017 |
_version_ | 1797338521437995008 |
---|---|
author | Mikereyi Aimaitijiang Ting-Ting Wu Ying-Ying Zheng Xian-Geng Hou Haitao Yang Yi Yang Xiang Xie |
author_facet | Mikereyi Aimaitijiang Ting-Ting Wu Ying-Ying Zheng Xian-Geng Hou Haitao Yang Yi Yang Xiang Xie |
author_sort | Mikereyi Aimaitijiang |
collection | DOAJ |
description | Background: The correlation between 5′-Nucleotidase (5′-NT) and the clinical outcomes in coronary artery disease (CAD) patients following percutaneous coronary intervention (PCI) is not clear. This study aims to clarify this relationship. Methods: The PRACTICE study enrolled 15,250 patients between December 2016 and October 2021. After filtering out those without 5′-NT data, a total of 6555 patients were analyzed with a median follow-up of 24 months. Based on the receiver operating characteristic (ROC) curve analysis, a 5′-NT level of 5.57 U/L was selected as the optimal cutoff value. All research samples were divided into high-value (≥5.57 U/L, n = 2346) and low-value groups (<5.57 U/L, n = 4209). Key clinical outcomes included all-cause death (ACD), cardiovascular death (CD), major adverse cardiovascular events (MACE), and major adverse cardiovascular and cerebrovascular events (MACCE). After separating patients into high and low value groups, multivariate Cox regression analysis was used to correct for potential confounding variables. Finally, risk ratios and their 95% confidence intervals (CIs) were calculated. Results: During the follow-up period, 129 instances of ACD were recorded—49 cases (1.2%) in the low-value group and 80 cases (3.4%) in the high-value group. Similarly, 102 CDs occurred, including 42 low-value group cases (1.0%) and 60 high-value group cases (2.6%). A total of 363 MACE occurred, including 198 low-value group cases (4.7%) and 165 high-value group cases (7%). A total of 397 cases of MACCE occurred, including 227 low-value group cases (5.4%) and 170 high-value group cases (7.2%). As serum 5′-NT increased, the incidence of ACD, CD, MACE and MACCE increased. After multivariate Cox regression, high 5′-NT levels were linked with a 1.63-fold increase in ACD risk (hazard ratio [HR] = 2.630, 95% CI: [1.770–3.908], p < 0.001) when compared to low 5′-NT patients. Similarly, the risk of CD, MACE, and MACCE increased by 1.298-fold (HR = 2.298, 95% CI: [1.477–3.573], p < 0.001), 41% (HR = 1.410, 95% CI: [1.124–1.768], p = 0.003) and 30.5% (HR = 1.305, 95% CI: [1.049–1.623], p = 0.017), respectively. Conclusions: high serum 5′-NT levels were independently correlated with adverse clinical outcomes in CAD patients following PCI, affirming its potential as a prognostic indicator. |
first_indexed | 2024-03-08T09:32:27Z |
format | Article |
id | doaj.art-f21bdda8dd6d4fafa22c5786ebb1ec0a |
institution | Directory Open Access Journal |
issn | 1530-6550 |
language | English |
last_indexed | 2024-03-08T09:32:27Z |
publishDate | 2024-01-01 |
publisher | IMR Press |
record_format | Article |
series | Reviews in Cardiovascular Medicine |
spelling | doaj.art-f21bdda8dd6d4fafa22c5786ebb1ec0a2024-01-31T01:12:56ZengIMR PressReviews in Cardiovascular Medicine1530-65502024-01-012511710.31083/j.rcm2501017S1530-6550(23)01132-8Serum 5′-Nucleotidase as a Novel Predictor of Adverse Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Coronary Artery DiseaseMikereyi Aimaitijiang0Ting-Ting Wu1Ying-Ying Zheng2Xian-Geng Hou3Haitao Yang4Yi Yang5Xiang Xie6Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, 830054 Urumqi, Xinjiang, ChinaDepartment of Cardiology, First Affiliated Hospital of Xinjiang Medical University, 830054 Urumqi, Xinjiang, ChinaDepartment of Cardiology, First Affiliated Hospital of Xinjiang Medical University, 830054 Urumqi, Xinjiang, ChinaDepartment of Cardiology, First Affiliated Hospital of Xinjiang Medical University, 830054 Urumqi, Xinjiang, ChinaDepartment of Cardiology, First Affiliated Hospital of Xinjiang Medical University, 830054 Urumqi, Xinjiang, ChinaDepartment of Cardiology, First Affiliated Hospital of Xinjiang Medical University, 830054 Urumqi, Xinjiang, ChinaDepartment of Cardiology, First Affiliated Hospital of Xinjiang Medical University, 830054 Urumqi, Xinjiang, ChinaBackground: The correlation between 5′-Nucleotidase (5′-NT) and the clinical outcomes in coronary artery disease (CAD) patients following percutaneous coronary intervention (PCI) is not clear. This study aims to clarify this relationship. Methods: The PRACTICE study enrolled 15,250 patients between December 2016 and October 2021. After filtering out those without 5′-NT data, a total of 6555 patients were analyzed with a median follow-up of 24 months. Based on the receiver operating characteristic (ROC) curve analysis, a 5′-NT level of 5.57 U/L was selected as the optimal cutoff value. All research samples were divided into high-value (≥5.57 U/L, n = 2346) and low-value groups (<5.57 U/L, n = 4209). Key clinical outcomes included all-cause death (ACD), cardiovascular death (CD), major adverse cardiovascular events (MACE), and major adverse cardiovascular and cerebrovascular events (MACCE). After separating patients into high and low value groups, multivariate Cox regression analysis was used to correct for potential confounding variables. Finally, risk ratios and their 95% confidence intervals (CIs) were calculated. Results: During the follow-up period, 129 instances of ACD were recorded—49 cases (1.2%) in the low-value group and 80 cases (3.4%) in the high-value group. Similarly, 102 CDs occurred, including 42 low-value group cases (1.0%) and 60 high-value group cases (2.6%). A total of 363 MACE occurred, including 198 low-value group cases (4.7%) and 165 high-value group cases (7%). A total of 397 cases of MACCE occurred, including 227 low-value group cases (5.4%) and 170 high-value group cases (7.2%). As serum 5′-NT increased, the incidence of ACD, CD, MACE and MACCE increased. After multivariate Cox regression, high 5′-NT levels were linked with a 1.63-fold increase in ACD risk (hazard ratio [HR] = 2.630, 95% CI: [1.770–3.908], p < 0.001) when compared to low 5′-NT patients. Similarly, the risk of CD, MACE, and MACCE increased by 1.298-fold (HR = 2.298, 95% CI: [1.477–3.573], p < 0.001), 41% (HR = 1.410, 95% CI: [1.124–1.768], p = 0.003) and 30.5% (HR = 1.305, 95% CI: [1.049–1.623], p = 0.017), respectively. Conclusions: high serum 5′-NT levels were independently correlated with adverse clinical outcomes in CAD patients following PCI, affirming its potential as a prognostic indicator.https://www.imrpress.com/journal/RCM/25/1/10.31083/j.rcm25010175′-nucleotidase (5′-nt)coronary artery disease (cad)cd73prognosis |
spellingShingle | Mikereyi Aimaitijiang Ting-Ting Wu Ying-Ying Zheng Xian-Geng Hou Haitao Yang Yi Yang Xiang Xie Serum 5′-Nucleotidase as a Novel Predictor of Adverse Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease Reviews in Cardiovascular Medicine 5′-nucleotidase (5′-nt) coronary artery disease (cad) cd73 prognosis |
title | Serum 5′-Nucleotidase as a Novel Predictor of Adverse Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease |
title_full | Serum 5′-Nucleotidase as a Novel Predictor of Adverse Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease |
title_fullStr | Serum 5′-Nucleotidase as a Novel Predictor of Adverse Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease |
title_full_unstemmed | Serum 5′-Nucleotidase as a Novel Predictor of Adverse Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease |
title_short | Serum 5′-Nucleotidase as a Novel Predictor of Adverse Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease |
title_sort | serum 5 nucleotidase as a novel predictor of adverse clinical outcomes after percutaneous coronary intervention in patients with coronary artery disease |
topic | 5′-nucleotidase (5′-nt) coronary artery disease (cad) cd73 prognosis |
url | https://www.imrpress.com/journal/RCM/25/1/10.31083/j.rcm2501017 |
work_keys_str_mv | AT mikereyiaimaitijiang serum5nucleotidaseasanovelpredictorofadverseclinicaloutcomesafterpercutaneouscoronaryinterventioninpatientswithcoronaryarterydisease AT tingtingwu serum5nucleotidaseasanovelpredictorofadverseclinicaloutcomesafterpercutaneouscoronaryinterventioninpatientswithcoronaryarterydisease AT yingyingzheng serum5nucleotidaseasanovelpredictorofadverseclinicaloutcomesafterpercutaneouscoronaryinterventioninpatientswithcoronaryarterydisease AT xiangenghou serum5nucleotidaseasanovelpredictorofadverseclinicaloutcomesafterpercutaneouscoronaryinterventioninpatientswithcoronaryarterydisease AT haitaoyang serum5nucleotidaseasanovelpredictorofadverseclinicaloutcomesafterpercutaneouscoronaryinterventioninpatientswithcoronaryarterydisease AT yiyang serum5nucleotidaseasanovelpredictorofadverseclinicaloutcomesafterpercutaneouscoronaryinterventioninpatientswithcoronaryarterydisease AT xiangxie serum5nucleotidaseasanovelpredictorofadverseclinicaloutcomesafterpercutaneouscoronaryinterventioninpatientswithcoronaryarterydisease |